期刊文献+

S100A14与MMP-2在卵巢高分化黏液性癌中的表达及相关性研究 被引量:1

Expressions and relationships of S100A14、MMP-2 in high differentiation of ovarian mucinous adenocarcinoma
暂未订购
导出
摘要 目的:探讨S100A14与基质金属蛋白酶-2(MMP-2)在卵巢高分化黏液性癌中的表达情况及两者之间的相关性。方法:免疫组化法检测23例正常卵巢组织、21例交界性卵巢黏液性肿瘤、75例卵巢高分化黏液性癌中S100A14与MMP-2的表达。结果:S100A14和MMP-2表达量在正常卵巢组织、交界性卵巢黏液性肿瘤、卵巢癌中的表达均呈递增趋势,两两比较差异均有统计学意义(P<0.05)。卵巢黏液性癌中,S100A14蛋白表达量与FIGO分期、有无淋巴结转移有关(P<0.01);MMP-2蛋白表达量与FIGO分期有关(P<0.01),而与淋巴结转移无关(P=0.342)。S100A14与MMP-2在卵巢黏液性癌中的表达呈正相关(P<0.01)。结论:S100A14与MMP-2表达升高与卵巢黏液性癌的发生、进展、早期转移相关,有可能成为治疗卵巢癌的新靶点和评估预后的有力指标。 Objective:To investigate the expressions of S100A14 and MMP-2 in high differentiation of ovarian mucinous carcinoma and evaluate their relationship. Methods:The ex-pressions of S100A14 and MMP-2 were examined by immunohistochemistry analysis in tissue microarrays which contains three kinds of tissues:normal ovarian tissues(23 cases),ovarian borderline mucinous neoplasm tissues(21 cases),high differentiation of ovarian mucinous carci-noma tissues(75 cases). Results:The expressions of S100A14 and MMP-2 demonstrate a rising trend in the three kinds of tissues, while there were statistical difference ( P 〈 0. 05 ). The S100A14 and MMP-2 expressions in mucinous ovarian adenocarcinoma tissue were obviously associated with FIGO stage(P〈0. 01). S100A14 expression was significantly higher in tissues with lymph node metastasis than those without lymph node metastasis in ovarian mucinous carci-noma (P〈0. 01). MMP-2 expression was higher(P〈0. 05)in lymph node-positive tissues than negative tissues among the early stage ovarian carcinoma(FIGO stage I ~ II),however,its ex-pression has no relationship with lymphatic metastasis in the high stage ovarian carcinoma(FI-GO stage III ~ IV) ( P = 0. 342). There was significant positive correlation between S100A14 and MMP-2 in high differentiation of ovarian mucinous carcinoma ( P 〈 0. 01). Conclusion:S100A14 and MMP-2 may pay responsibility for the process of carcinogenesis,progression and lymphatic metastasis. S100A14 and MMP-2 may be useful targets for treatment of ovarian carci-noma and a powerful index to estimate prognosis.
出处 《现代妇产科进展》 CSCD 北大核心 2015年第8期602-604,共3页 Progress in Obstetrics and Gynecology
关键词 S100A14 MMP-2 免疫组化 卵巢粘液性癌 Immunohistochemistry Ovarian mucinous carcinoma
  • 相关文献

参考文献14

  • 1孔北华,Wen-xin ZHENG.重视卵巢癌的二元论模型与卵巢外起源新说[J].中华妇产科杂志,2011,46(10):721-723. 被引量:17
  • 2Frumovitz M, Schmeler KM, Malpica A, et al. Unmasking the complexities of mucinous ovarian carcinoma[J]. Gy- necol Oncol, 2010,117 ( 3 ) :491-496.
  • 3Chen H,Yuan Y ,Liu Z,et al. Involement of S100A14 pro- tein in cell invasion by affecting expression and function of MMP-2 via p53-dependant transcriptional regulation [ J ].Biol Chem,2012,287(21 ) :17109-17119.
  • 4Mckiernan E, McDermott EW, Evoy D, et al. The role of SIO0 genes in breast cancer progression [ J ]. Tumour Bi- ol,2011,32(3) :441-450.
  • 5Kim G,Chung JY,Jnn SY,et al. Loss of S100A14 expres- sion is associated with the progression of adenoearcinomas of the small intestine[ J]. Pathbio1,2013,80(2) :95-101.
  • 6蔡威,宋今丹.基质金属蛋白酶及其组织抑制物在卵巢肿瘤中的表达[J].癌症,2002,21(1):91-94. 被引量:29
  • 7Pietas A, Schluns K, Marenhole I. Molecular cloning and characterization of the human S100A14 gene encoding a novel member of the $100 family[ J ]. Genomics,2002,79 (4) :513-522.
  • 8Xu C, Chen H, Liu Z, et al. S100A14, a member of the EF-hand Calcium-binding prcteins, is overexpressed in breast cancer and acts as a modulator of HER2 signaling [ J]. Biol Chem,2014,289(2) :827-837.
  • 9Chert H,Xu C,lin Q,et al. S100 protein family in human cancer[ J]. Am Cancer Res,2014,4(2) :89-115.
  • 10Cho H,Shin HY,Kim JS,et al. The role of S100A14 in epithelial ovarian tumors[J]. Oncotarget, 2014,5 ( 11 ) : 3482-3496.

二级参考文献24

  • 1Shih IeM, Kurman RJ. Ovarian tumorigenesis: a proposed model based on morphological and molecular genetic analysis. Am J Pathol, 2004,164 : 1511-1518.
  • 2Malpica A, Deavers MT, Lu K, et al. Grading ovarian serous carcinoma using a two-tier system. Am J Surg Pathol,2004,28 : 496-504.
  • 3Crum CP, Drapkin R, Miron A, et al. The distal fallopian tube: a new model for pelvic serous carcinogenesis. Curr Opin Obstet Gynecol, 2007,19 : 3-9.
  • 4Levanon K, Crum C, Drapkin R. New insights into the pathogenesis of serous ovarian cancer and its clinical impact. J Clin Oneo1,2008 ,26 :5284-5293.
  • 5Kurman R J, Shih IeM. Molecular pathogenesis and extraovarian origin of epithelial ovarian cancer: shifting the paradigm. Hum Pathol, 2011,42 : 918-931.
  • 6Wiegand KC, Shah SP, A1-Agha OM, et al. ARIDIA mutations in endometriosis-associated ovarian carcinomas. N Engl J Med, 2010,363 : 1532-1543.
  • 7Buys SS, Partridge E, Black A, et al. Effect of screening on ovarian cancer mortality : the Prostate, Lung, Colorectal and Ovarian (PLCO) Cancer Screening Randomized Controlled Trial. JAMA ,2011,305:2295-2303.
  • 8Medeiros F, Muto MG, Lee Y, et al. The tubal fimbria is a preferred site for early adenocarcinoma in women with familial ovarian cancer syndrome. Am J Surg Pathol,2006,30:230-236.
  • 9Kachra Z,Beaulieu E,Delbecchi L,et al.Expression of matrix metalloproteinaes and their inhibitors in human brain tumors [J].Clin Exp metastasis,1999,17: 555-566.
  • 10Liotta LA,Stetler-Stevenson WG.Tumor invasion and metastasis: an imbalance of positive and negative regulation [J].Cancer Res (suppl),1991,51: 5054s-5059s.

共引文献44

同被引文献8

引证文献1

二级引证文献2

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部